Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Necchi , Petros Grivas , Gennady Bratslavsky , Oleg Shapiro , Joseph Jacob , Ethan Sokol , Jo-Anne Vergilio , Keith Killian , Douglas I. Lin , Shakti H. Ramkissoon , Eric Allan Severson , Amanda Hemmerich , Jon Chung , Brian Michael Alexander , Prasanth Reddy , Kimberly McGregor , Julia Andrea Elvin , Alexa Betzig Schrock , Natalie Danziger , Jeffrey S. Ross
Background: CGP was performed on Pre PT and Post MET including bone (BO), liver (LIV), lung (LU), brain (BN), lymph node (LN) and soft tissue (ST) mPC. Methods: 1,294 mPC underwent hybrid-capture based CGP. Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci. PD-L1 expression was determined by IHC (Dako 22C3). Results: GA in AR were lowest in the Pre PT (2%) and highest in Post LU (24%) and LIV (50%). GA/tumor was significantly higher in BN (8.0) compared to PT (3.8). BR MET also featured higher PTEN GA than PT. BRCA2 GA varied from 0% in BR to 7-9% in PT, BO, LU, LN and ST to a high of 15% in LI MET. ATM GA were significantly higher in LU MET and RAD21 GA highest in LN MET. Potential predictors of IO drug response included high CDK12 GA in LU MET, MSI high status at 29% in BR MET associated with higher TMB levels, but virtual absence of high PD-L1 expression. ERBB2 GA appeared to be increased in the MET group compared with PT but BRAF GA were not. RB1 GA were significantly increased in LIV MET cases. Conclusions: CGP of mPC PT and MET demonstrates significant differences likely linked to exposure to systemic therapies. These findings suggest that, in the future, liquid biopsies may have advantages over individual MET site biopsies in their ability to capture the entire range of therapeutic opportunities for patients with advanced mPC.
Pre | Post | LIV | LU | BN | LN | ST | |
---|---|---|---|---|---|---|---|
PT | BO | ||||||
Cases | 770 | 127 | 34 | 25 | 7 | 205 | 126 |
Median age (range) | 64 (39-89+) | 68 (44-89+) | 69 (48-84) | 70 (50-86) | 75 (58-84) | 68 (39-89+) | 68 (44-89+) |
GA/tumor | 3.8 | 5.0 | 5.1 | 4.2 | 8.0 | 4.8 | 5.0 |
TMPRSS2:ERG | 35% | 27% | 32% | 32% | 29% | 40% | 27% |
AR | 2% | 31% | 50% | 24% | 43% | 33% | 31% |
TP53 | 37% | 41% | 56% | 28% | 57% | 50% | 41% |
PTEN | 24% | 38% | 38% | 32% | 86% | 42% | 38% |
BRCA2 | 9% | 8% | 15% | 8% | 0% | 7% | 8% |
ATM | 6% | 6% | 0% | 24% | 0% | 5% | 6% |
RAD21 | 9% | 6% | 9% | 8% | 0% | 11% | 6% |
MYC | 7% | 10% | 9% | 8% | 14% | 18% | 10% |
PIK3CA | 7% | 6% | 3% | 8% | 14% | 6% | 6% |
RB1 | 4% | 9% | 30% | 0% | 0% | 5% | 9% |
APC | 8% | 12% | 18% | 8% | 29% | 6% | 10% |
CDK12 | 5% | 10% | 0% | 16% | 0% | 5% | 10% |
BRAF | 4% | 3% | 6% | 0% | 0% | 3% | 3% |
ERBB2 | 0.6% | 5% | 3% | 8% | 0% | 2% | 5% |
MSI-High | 2% | 5% | 7% | 0% | 29% | 2% | 5% |
Median TMB | 1.3 | 2.5 | 2.5 | 2.5 | 7.5 | 2.5 | 2.5 |
TMB>10/20 mut/Mb | 5%/3% | 7%/4% | 9%/3% | 0%/0% | 43%/29% | 4%/2% | 7%/4% |
PD-L1 IHC Low Positive | 8%/0% | 3%/0% | 15%/0% | 13%/0% | 0%/0% | 4%/4% | 3%/0% |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Rebecca A Sager
2022 ASCO Annual Meeting
First Author: Petros Grivas
2022 ASCO Genitourinary Cancers Symposium
First Author: Petros Grivas
2022 ASCO Genitourinary Cancers Symposium
First Author: Gennady Bratslavsky